Cargando…
Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial
BACKGROUND: Pacemakers are widely utilised to treat bradycardia, but right ventricular (RV) pacing is associated with heightened risk of left ventricular (LV) systolic dysfunction and heart failure. We aimed to compare personalised pacemaker reprogramming to avoid RV pacing with usual care on echoca...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668131/ https://www.ncbi.nlm.nih.gov/pubmed/34898655 http://dx.doi.org/10.1371/journal.pone.0259450 |
_version_ | 1784614506432823296 |
---|---|
author | Paton, Maria F. Gierula, John Lowry, Judith E. Cairns, David A. Bose Rosling, Kieran Cole, Charlotte A. McGinlay, Melanie Straw, Sam Byrom, Rowena Cubbon, Richard M. Kearney, Mark T. Witte, Klaus K. |
author_facet | Paton, Maria F. Gierula, John Lowry, Judith E. Cairns, David A. Bose Rosling, Kieran Cole, Charlotte A. McGinlay, Melanie Straw, Sam Byrom, Rowena Cubbon, Richard M. Kearney, Mark T. Witte, Klaus K. |
author_sort | Paton, Maria F. |
collection | PubMed |
description | BACKGROUND: Pacemakers are widely utilised to treat bradycardia, but right ventricular (RV) pacing is associated with heightened risk of left ventricular (LV) systolic dysfunction and heart failure. We aimed to compare personalised pacemaker reprogramming to avoid RV pacing with usual care on echocardiographic and patient-orientated outcomes. METHODS: A prospective phase II randomised, double-blind, parallel-group trial in 100 patients with a pacemaker implanted for indications other than third degree heart block for ≥2 years. Personalised pacemaker reprogramming was guided by a published protocol. Primary outcome was change in LV ejection fraction on echocardiography after 6 months. Secondary outcomes included LV remodeling, quality of life, and battery longevity. RESULTS: Clinical and pacemaker variables were similar between groups. The mean age (SD) of participants was 76 (+/-9) years and 71% were male. Nine patients withdrew due to concurrent illness, leaving 91 patients in the intention-to-treat analysis. At 6 months, personalised programming compared to usual care, reduced RV pacing (-6.5±1.8% versus -0.21±1.7%; p<0.01), improved LV function (LV ejection fraction +3.09% [95% confidence interval (CI) 0.48 to 5.70%; p = 0.02]) and LV dimensions (LV end systolic volume indexed to body surface area -2.99mL/m(2) [95% CI -5.69 to -0.29; p = 0.03]). Intervention also preserved battery longevity by approximately 5 months (+0.38 years [95% CI 0.14 to 0.62; p<0.01)) with no evidence of an effect on quality of life (+0.19, [95% CI -0.25 to 0.62; p = 0.402]). CONCLUSIONS: Personalised programming in patients with pacemakers for bradycardia can improve LV function and size, extend battery longevity, and is safe and acceptable to patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03627585. |
format | Online Article Text |
id | pubmed-8668131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-86681312021-12-14 Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial Paton, Maria F. Gierula, John Lowry, Judith E. Cairns, David A. Bose Rosling, Kieran Cole, Charlotte A. McGinlay, Melanie Straw, Sam Byrom, Rowena Cubbon, Richard M. Kearney, Mark T. Witte, Klaus K. PLoS One Research Article BACKGROUND: Pacemakers are widely utilised to treat bradycardia, but right ventricular (RV) pacing is associated with heightened risk of left ventricular (LV) systolic dysfunction and heart failure. We aimed to compare personalised pacemaker reprogramming to avoid RV pacing with usual care on echocardiographic and patient-orientated outcomes. METHODS: A prospective phase II randomised, double-blind, parallel-group trial in 100 patients with a pacemaker implanted for indications other than third degree heart block for ≥2 years. Personalised pacemaker reprogramming was guided by a published protocol. Primary outcome was change in LV ejection fraction on echocardiography after 6 months. Secondary outcomes included LV remodeling, quality of life, and battery longevity. RESULTS: Clinical and pacemaker variables were similar between groups. The mean age (SD) of participants was 76 (+/-9) years and 71% were male. Nine patients withdrew due to concurrent illness, leaving 91 patients in the intention-to-treat analysis. At 6 months, personalised programming compared to usual care, reduced RV pacing (-6.5±1.8% versus -0.21±1.7%; p<0.01), improved LV function (LV ejection fraction +3.09% [95% confidence interval (CI) 0.48 to 5.70%; p = 0.02]) and LV dimensions (LV end systolic volume indexed to body surface area -2.99mL/m(2) [95% CI -5.69 to -0.29; p = 0.03]). Intervention also preserved battery longevity by approximately 5 months (+0.38 years [95% CI 0.14 to 0.62; p<0.01)) with no evidence of an effect on quality of life (+0.19, [95% CI -0.25 to 0.62; p = 0.402]). CONCLUSIONS: Personalised programming in patients with pacemakers for bradycardia can improve LV function and size, extend battery longevity, and is safe and acceptable to patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03627585. Public Library of Science 2021-12-13 /pmc/articles/PMC8668131/ /pubmed/34898655 http://dx.doi.org/10.1371/journal.pone.0259450 Text en © 2021 Paton et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Paton, Maria F. Gierula, John Lowry, Judith E. Cairns, David A. Bose Rosling, Kieran Cole, Charlotte A. McGinlay, Melanie Straw, Sam Byrom, Rowena Cubbon, Richard M. Kearney, Mark T. Witte, Klaus K. Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial |
title | Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial |
title_full | Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial |
title_fullStr | Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial |
title_full_unstemmed | Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial |
title_short | Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial |
title_sort | personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: a phase ii randomised, controlled clinical trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668131/ https://www.ncbi.nlm.nih.gov/pubmed/34898655 http://dx.doi.org/10.1371/journal.pone.0259450 |
work_keys_str_mv | AT patonmariaf personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial AT gierulajohn personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial AT lowryjudithe personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial AT cairnsdavida personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial AT boseroslingkieran personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial AT colecharlottea personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial AT mcginlaymelanie personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial AT strawsam personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial AT byromrowena personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial AT cubbonrichardm personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial AT kearneymarkt personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial AT witteklausk personalisedreprogrammingtopreventprogressivepacemakerrelatedleftventriculardysfunctionaphaseiirandomisedcontrolledclinicaltrial |